|Day Low/High||69.66 / 70.77|
|52 Wk Low/High||50.77 / 92.18|
Clinical Outcomes in Patients with High Recurrence Score® Results Presented Today in Oral Session at ESMO 2019 Congress
NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Bancorp of New Jersey, Inc.
NEW YORK, Sept. 6, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.
- Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy
NEW YORK, Aug. 9, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Genomic Health, Inc.
NEW ORLEANS, Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc.
MILWAUKEE, July 29, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Genomic (Nasdaq: GHDX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Genomic to Exact Sciences.
Cancer diagnostics company Exact Sciences will acquire healthcare company Genomic Health for about $2.8 billion.
SAN DIEGO, July 29, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Genomic Health, Inc.
U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.
Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth
Cancer diagnostics company Exact Sciences is in advanced talks to acquire Genomic Health for about $2.8 billion to strengthen its cancer-testing offerings, according to Bloomberg.
REDWOOD CITY, Calif., July 25, 2019 /PRNewswire/ -- Genomic Health, Inc.
NEW YORK, July 23, 2019 /PRNewswire/ -- Genomic Health Inc. (NASD: GHDX) will replace Electronics For Imaging Inc.
Reimbursement Decision Follows IQWiG's Recommendation Based on TAILORx Study Results
Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting TAILORx Continues to Elevate Oncotype DX ® to a New Global Standard with Increasing Utilization and...
New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial to be Presented at ASCO Annual Meeting Today REDWOOD...
REDWOOD CITY, Calif., May 29, 2019 /PRNewswire/ -- Genomic Health, Inc.
Delivered $108.8M in Revenue and Growth of 17.4 Percent
REDWOOD CITY, Calif., April 30, 2019 /PRNewswire/ -- Genomic Health, Inc.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
Investors in Genomic Health Inc saw new options become available this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GHDX options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:
Investors in Genomic Health Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GHDX options chain for the new August 17th contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $33.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $32.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.